News

AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program. The trial showed that anselamimab, a light chain depleter ...